Ivo Valter
About
Ivo Valter is a scholar working on Pathology and Forensic Medicine, Orthopedics and Sports Medicine and Oncology.
According to data from OpenAlex, Ivo Valter has authored 28 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 11 papers in Orthopedics and Sports Medicine and 10 papers in Oncology. Recurrent topics in Ivo Valter's work include Bone health and treatments (10 papers), Bone health and osteoporosis research (10 papers) and Systemic Sclerosis and Related Diseases (10 papers). Ivo Valter is often cited by papers focused on Bone health and treatments (10 papers), Bone health and osteoporosis research (10 papers) and Systemic Sclerosis and Related Diseases (10 papers). Ivo Valter collaborates with scholars based in United States, Denmark and Estonia. Ivo Valter's co-authors include Jacques P. Brown, Jens‐Erik Beck Jensen, Nigel Gilchrist, Christian Roux, Michael R. McClung, Steven R. Cummings, Serge Ferrari, Ove Törring, Richard Eastell and H R Maricq and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Journal of Clinical Epidemiology.
In The Last Decade
Ivo Valter
26 papers receiving 1.3k citations
Hit Papers
Peers
Ivo Valter
A Montagnani Italy
Osvaldo Daniel Messina Argentina
Tiziana Campa Italy
Charles-Joël Menkès France
B. Lucani Italy
M. Yeates Australia
Robert H. Caplan United States
V. Nunziata Italy
Y. Boutsen Belgium
S. Thomas United States
Citations per year, relative to Ivo Valter Ivo Valter (= 1×)
peers
A Montagnani
Countries citing papers authored by Ivo Valter
Since
Specialization
Citations
This map shows the geographic impact of Ivo Valter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivo Valter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivo Valter more than expected).
Fields of papers citing papers by Ivo Valter
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ivo Valter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivo Valter. The network helps show where Ivo Valter may publish in the future.
Co-authorship network of co-authors of Ivo Valter
This figure shows the co-authorship network connecting the top 25 collaborators of Ivo Valter. A scholar is included among the top collaborators of Ivo Valter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivo Valter. Ivo Valter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pluskiewicz, Wojciech, Jerzy Supronik, Corinne Petit-Frère, et al.. (2025). LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis. Journal of the Endocrine Society. 9(12). bvaf164–bvaf164.
2.
Valter, Ivo, et al.. (2024). A randomized, double-blind, study to evaluate the efficacy, pharmacodynamics, safety and immunogenicity of FKS518 proposed biosimilar to denosumab with the originator in postmenopausal women with osteoporosis (LUMIADE-3 study).. Journal of Clinical Oncology. 42(16_suppl). 3155–3155.
3.
Coates, Laura C., Sreekumar Pillai, Hasan Tahir, et al.. (2021). Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study. Arthritis & Rheumatology. 73(9). 1663–1672.
4.
Recker, Robert R., David W. Dempster, Bente Langdahl, et al.. (2020). Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension. Journal of Bone and Mineral Research. 35(7). 1289–1299.
5.
Bihlet, Asger Reinstrup, I. Byrjalsen, Anne‐Christine Bay‐Jensen, et al.. (2018). Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis. BMC Musculoskeletal Disorders. 19(1). 17–17.
6.
Dempster, David W., Jacques P. Brown, Astrid Fahrleitner‐Pammer, et al.. (2018). Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 103(7). 2498–2509.
7.
Cosman, Felicia, Paul D. Miller, Gregory C. Williams, et al.. (2017). Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis. Mayo Clinic Proceedings. 92(2). 200–210.
8.
Cummings, Steven R., Serge Ferrari, Richard Eastell, et al.. (2017). Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. Journal of Bone and Mineral Research. 33(2). 190–198.
9.
Henriksen, Kim, I. Byrjalsen, J.R. Andersen, et al.. (2016). A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Bone. 91. 122–129.
10.
Bihlet, Asger Reinstrup, M.A. Karsdal, I. Byrjalsen, et al.. (2016). OP0092 Identification of Pain Subtypes Associated with Placebo-Response: Data from Two Phase 3 Randomized Clinical Trials in Symptomatic Knee Osteoarthritis. Annals of the Rheumatic Diseases. 75. 89–90.
11.
Brown, Jacques P., Ian R. Reid, Rachel B. Wagman, et al.. (2014). Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension. Journal of Bone and Mineral Research. 29(9). 2051–2056.
12.
Brown, Jacques P., Rachel B. Wagman, David W. Dempster, et al.. (2013). OP0251 Bone Histology and Histomorphometry: Effects of 5 Years of Denosumab in the Freedom Study Extension. Annals of the Rheumatic Diseases. 72. A137–A138.
13.
Henriksen, Kim, J.R. Andersen, B.J. Riis, et al.. (2012). Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis. Bone. 53(1). 160–166.
14.
Mäestu, Jarek, Alon Eliakim, Jaak Jürimäe, Ivo Valter, & Toivo Jürimäe. (2010). Anabolic and Catabolic Hormones and Energy Balance of the Male Bodybuilders During the Preparation for the Competition. The Journal of Strength and Conditioning Research. 24(4). 1074–1081.
15.
Mäestu, Jarek, Jaak Jürimäe, Ivo Valter, & Toivo Jürimäe. (2008). Increases in ghrelin and decreases in leptin without altering adiponectin during extreme weight loss in male competitive bodybuilders. Metabolism. 57(2). 221–225.
16.
Palesch, Yuko Y., Ivo Valter, P. Carpentier, & Hildegard R. Maricq. (1999). Association between Cigarette and Alcohol Consumption and Raynaud’s Phenomenon. Journal of Clinical Epidemiology. 52(4). 321–328.
17.
Maricq, H R, et al.. (1998). An objective method to estimate the severity of Raynaud phenomenon: digital blood pressure response to cooling. Vascular Medicine. 3(2). 109–113.
18.
Valter, Ivo & H R Maricq. (1997). Prevalence of Raynaud Phenomenon in Tartu and Tartumaa, Southern Estonia. Scandinavian Journal of Rheumatology. 26(2). 117–124.
19.
Valter, Ivo, et al.. (1997). Prevalence of Scleroderma Spectrum Disorders in the General Population of Estonia. Scandinavian Journal of Rheumatology. 26(6). 419–425.
20.
Maricq, H R, et al.. (1996). Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.. PubMed. 23(12). 2068–78.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A Montagnani Breakdown of academic impact, for papers by Osvaldo Daniel Messina Breakdown of academic impact, for papers by Tiziana Campa Breakdown of academic impact, for papers by Charles-Joël Menkès Breakdown of academic impact, for papers by B. Lucani Breakdown of academic impact, for papers by M. Yeates Breakdown of academic impact, for papers by Robert H. Caplan Breakdown of academic impact, for papers by V. Nunziata Breakdown of academic impact, for papers by Y. Boutsen Breakdown of academic impact, for papers by S. Thomas